22nd century group (nasdaq: xxii) begins integration of gvb biopharma, creating a complete, robust hemp/cannabis platform

Buffalo, n.y., may 18, 2022 (globe newswire) -- 22nd century group, inc. (nasdaq: xxii), a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, today announced that it has begun integration of gvb biopharma, which it acquired on may 13, 2022. as a contract development and manufacturing organization (cdmo), gvb is a market share leader in hemp-derived active ingredients for the nutraceuticals, pharmaceutical and consumer goods industries. 22nd century has posted a presentation, which includes an overview of gvb's business operations, the compelling strategic benefits of the acquisition, and strengths of the combined companies, on the investors section of its website, at xxiicentury.com .
XXII Ratings Summary
XXII Quant Ranking